Lamerz R, Stieber P, Fateh-Moghadam A
Medical Department II, University of Munich, Germany.
In Vivo. 1993 Nov-Dec;7(6B):607-13.
Breast cancer markers (TM) are mainly useful for monitoring the course of disease after diagnosis and first line treatment with the control options of primary treatments early recognition of reactivation and efficiency control of palliative treatment. The best single and established marker is a polymorphic epithelial mucin of the MUC-1 family the prototype of which is CA 15-3 (successive markers: MCA, CA-549, TAG-12, CAM 26/29) followed by CEA with lower diagnostic sensitivity and specificity and TPA/TPS reflecting more the proliferative activity. Besides former TM combinations of CEA with one or more less specific markers (e.g. PAM, CRP, beta 2m, ferritin, GCDFP, HCG, total or boney AP, gamma GT), more recent studies recommend the use of fewer markers such as TPA/TPS + CEA or CA 15-3, CA 15-3 + CEA or MCA, CA M26 + CA M29, TAG12 + CA 15-3 + MCA and CEA + CA 15-3 + ESR.
乳腺癌标志物（TM）主要用于在诊断和一线治疗后监测疾病进程，以及通过初级治疗的对照选项早期识别再激活情况和控制姑息治疗的效果。最佳的单一且已确立的标志物是MUC-1家族的一种多态性上皮粘蛋白，其原型是CA 15-3（后续标志物：MCA、CA-549、TAG-12、CAM 26/29），其次是CEA，其诊断敏感性和特异性较低，而TPA/TPS更多地反映增殖活性。除了以前将CEA与一种或多种特异性较低的标志物（如PAM、CRP、β2m、铁蛋白、GCDFP、HCG、总碱性磷酸酶或骨碱性磷酸酶、γ-GT）组合使用的TM外，最近的研究推荐使用较少的标志物，如TPA/TPS + CEA或CA 15-3、CA 15-3 + CEA或MCA、CA M26 + CA M29、TAG12 + CA 15-3 + MCA以及CEA + CA 15-3 + ESR。
